Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
批准号:
7648344
负责人:
ELIZABETH MARY SWISHER
金额:
$32.37万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-08 至 2014-02-28
关键词:
AgeAllelesBRCA1 MutationBRCA1 geneCDKN1B geneCDKN1C geneCarcinomaCellsChemopreventionChildClinicalDevelopmentDiseaseEarly DiagnosisEpithelialEpitheliumFemaleFrequenciesGene Expression ProfileGenesGenital systemGoalsHereditary Ovarian CarcinomaHigh Risk WomanImmunohistochemistryInheritedLeadLesionLocationMalignant - descriptorMalignant NeoplasmsMammalian OviductsMicroinvasiveMolecular ProfilingMutationNeoplasmsOperative Surgical ProceduresOvarianOvarian CarcinomaPeritonealPhenotypePremalignantPreventionPrevention strategyPreventiveProteinsProtocols documentationQuantitative Reverse Transcriptase PCRRecommendationRiskSalpingo-OophorectomyScreening procedureSerousSpecimenTP53 geneTimeWomandesignfimbriahigh riskimprovedlifetime riskmalignant phenotypemutation carrierneoplastic cellnovel strategiesovarian neoplasmprotein expressionpublic health relevancetumorigenesis
中文摘要
描述(由申请人提供):缺乏可识别的卵巢癌前病变阻碍了对这种致命疾病进行合理监测和化学预防的尝试。事实上,目前还不确定哪些是女性生殖道中转化为卵巢和原发性腹膜恶性肿瘤的特定细胞。更好地了解卵巢肿瘤发生的早期步骤将有助于制定新的筛查和预防策略。BRCA1基因的遗传突变导致大约40%的卵巢癌、输卵管癌或腹膜癌的终生风险。目前对BRCA1突变女性的临床建议包括在40岁完成生育后进行输卵管卵巢切除术(RRSO)以降低风险。我们的研究小组和其他研究小组已经发现,在接受RRSO的BRCA 1突变携带者中,输卵管高度恶性浆液性肿瘤的发生率很高。当使用详细的手术和病理方案时,隐匿性输卵管肿瘤的发生率超过卵巢肿瘤。我们假设大多数BRCA1突变携带者的卵巢癌和腹膜癌是由输卵管中的肿瘤细胞引起的。这种现象可能对散发性和遗传性卵巢癌的发展有重要意义。目前建议的总体目标是确定遗传性BRCA1突变妇女的癌前输卵管表型。该提案的具体目标是:1.描述未受影响的BRCA1突变女性和BRCA1相关或散发性卵巢癌和腹膜癌女性的输卵管上皮特征。2.鉴定和表征BRCA1突变妇女病理正常输卵管上皮癌前病变相关的基因表达特征3.评估遗传性和散发性卵巢癌和腹膜癌中特异性目标2的优先基因。公共卫生相关性:需要对卵巢癌发展的早期步骤有更好的理解,以促进合理和新的筛查和预防策略。确定卵巢癌和腹膜癌的前体病变并证明其恶性进展的可能性,将有助于在高危妇女中进行化学预防试验,并为早期检测提供新的靶点。
英文摘要
DESCRIPTION (provided by applicant): The lack of an identifiable precursor lesion for ovarian carcinoma hinders attempts to design rational surveillance and chemoprevention for this deadly disease. Indeed, it is uncertain which are the specific cells in the female genital tract that transform into ovarian and primary peritoneal malignancies. A better understanding of the early steps in ovarian tumorigenesis would facilitate the development of new screening and prevention strategies. Inherited mutations in the BRCA1 gene result in an approximate 40% lifetime risk of ovarian, tubal or peritoneal carcinoma. Current clinical recommendations for women with BRCA1 mutations include risk-reducing salpingo-oophorectomy (RRSO) by age 40 after completion of child-bearing. Our group and others have identified a high rate of high-grade serous neoplasia in the fallopian tubes of BRCA1 mutation carriers undergoing RRSO. The frequency of occult tubal neoplasia exceeds that of ovarian neoplasia when using a detailed surgical and pathological protocol. We hypothesize that most ovarian and peritoneal carcinomas arising in BRCA1 mutation carriers are seeded from neoplastic cells arising in the fallopian tubes. This phenomenon could have important implications for the development of sporadic as well as hereditary ovarian carcinoma. The overall goal of the current proposal is to define a premalignant tubal phenotype in women with inherited BRCA1 mutations. The specific aims of this proposal are: 1. Characterize tubal epithelium in unaffected women with BRCA1 mutations and in women with BRCA1- associated or sporadic ovarian and peritoneal carcinomas. 2. Identify and characterize a gene expression signature associated with premalignant alterations in pathologically normal tubal epithelium from women with BRCA1 mutations. 3. Evaluate priority genes from Specific Aim 2 in inherited and sporadic ovarian and peritoneal carcinomas. PUBLIC HEALTH RELEVANCE: An improved understanding of the early steps in ovarian carcinoma development is needed to facilitate rational and novel strategies for screening and prevention. Identification of a pre-cursor lesion for ovarian and peritoneal carcinoma and proof of its potential for malignant progression would facilitate chemoprevention trials in high-risk women and provide new targets for early detection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer
-
批准号:10661251
-
项目类别:
-
资助金额:$64.9万
-
财政年份:2023
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
-
批准号:10028143
-
项目类别:
-
资助金额:$45.95万
-
财政年份:2020
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
-
批准号:10405502
-
项目类别:
-
资助金额:$45.5万
-
财政年份:2020
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
-
批准号:10200719
-
项目类别:
-
资助金额:$44.57万
-
财政年份:2020
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Combined Methylation and Mutation to Predict Response to PARP Inhibitors
-
批准号:9893364
-
项目类别:
-
资助金额:$64.52万
-
财政年份:2020
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Combined Methylation and Mutation to Predict Response to PARP Inhibitors
-
批准号:10378133
-
项目类别:
-
资助金额:$59.67万
-
财政年份:2020
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Combined Methylation and Mutation to Predict Response to PARP Inhibitors
-
批准号:10670755
-
项目类别:
-
资助金额:$58.53万
-
财政年份:2020
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Implementing the moon: Getting genomic testing to the public
-
批准号:10228866
-
项目类别:
-
资助金额:$13.49万
-
财政年份:2019
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
-
批准号:7837669
-
项目类别:
-
资助金额:$32.37万
-
财政年份:2009
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
-
批准号:8068733
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2009
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
-
批准号:8445430
-
项目类别:
-
资助金额:$29.52万
-
财政年份:2009
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Clinical Implication of the Acquisition of BRCA1/2 Function in BRCA1/2-Deflcient
-
批准号:7727522
-
项目类别:
-
资助金额:$28.5万
-
财政年份:2009
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
-
批准号:8234168
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2009
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Genetic and Epigenetic Markers in Ovarian Cancer
-
批准号:7122817
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2002
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Genetic and Epigenetic Markers in Ovarian Cancer
-
批准号:6787334
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2002
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Genetic and Epigenetic Markers in Ovarian Cancer
-
批准号:6937172
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2002
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Genetic and Epigenetic Markers in Ovarian Cancer
-
批准号:6666840
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2002
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Genetic and Epigenetic Markers in Ovarian Cancer
-
批准号:6507573
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2002
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Clinical Implication of the Acquisition of BRCA1/2 Function in BRCA1/2-Deflcient
-
批准号:8523019
-
项目类别:
-
资助金额:$26.28万
-
财政年份:--
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
Clinical Implication of the Acquisition of BRCA1/2 Function in BRCA1/2-Deflcient
-
批准号:8077356
-
项目类别:
-
资助金额:$27.37万
-
财政年份:--
-
负责人:ELIZABETH MARY SWISHER
-
依托单位:
海外基金